Hyphens, Medac Expand Tie-Up to Bring Rheumatoid Arthritis Pen to Thailand, Cambodia
MT Newswires
Oct 16, 2025
Hyphens Pharma International's (SGX:1J5) subsidiary, Hyphens Pharma, expanded its partnership with German pharmaceutical firm, Medac Gesellschaft, to bring its Metoject subcutaneous autoinjector pen to Thailand and Cambodia.
The extension is part of an existing agreement that allows Hyphens to have exclusive rights to register and market the Meteoject subcutaneous autoinjector pen, according to a Thursday filing with the Singapore Exchange.
The pen is approved and available in 15 countries and is considered a first-line treatment for rheumatoid arthritis.
Shares of the company were down nearly 2% at the close of trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.